![](/images/Company_Logo/company_logo_default.png)
Targeted Molecules Corporation Profile last edited on: 9/16/2008
CAGE:
UEI:
Business Identifier: Targeted drug therapies using a proprietary in vivo drug discovery platform. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 50
County: San Diego
Congr. District: 50
County: San Diego
Public Profile
During 2005 Targeted Molecules Corporation was acquired by Chromos. Targeted Molecules Corporation (TMC) exploits a unique technology platform, in vivo screening of phage combinatorial libraries for peptides that home selectively to specific tissues or sites of disease. Targeted Molecules is a developer of novel antibody therapeutics in the validated class of drugs known as Selective Adhesion Molecule Inhibitors (SAMI). The company is currently focused on the advancement of two SAMI antibodies that address unmet medical needs in the areas of chronic inflammation and acute thrombosis.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
500+Revenue Range
Over 50MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2006 | 1 | NIH | $139,050 | |
Project Title: A platelet ligand mimetic for neurothrombotic disorders | ||||
2001 | 1 | NIH | $100,000 | |
Project Title: Novel prostate homing peptides as potential diagnostics |
Key People / Management
Elias Lazarides -- President
Paul Cayer -- CFO & SVP, Business Development
Catherine M Woods -- Executive Director, Biological Research & Extramural Affairs
Paul Cayer -- CFO & SVP, Business Development
Catherine M Woods -- Executive Director, Biological Research & Extramural Affairs
Company News
There are no news available.